Kelly J A, Otto-Salaj L L, Sikkema K J, Pinkerton S D, Bloom F R
Center for AIDS Intervention Research, Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee 53226, USA.
Health Psychol. 1998 Jul;17(4):310-9. doi: 10.1037//0278-6133.17.4.310.
Protease inhibitor combination therapies can reduce HIV viral load, improve immune system functioning, and decrease mortality from AIDS. These medical developments raise a host of critical new issues for behavioral research on HIV/AIDS. This article reviews developments in HIV combination therapy regimens and behavioral factors involved in these regimens and focuses on four key behavioral research areas: (a) the development of interventions to promote treatment adherence, (b) psychological coping with HIV/AIDS in the context of new treatments for the disease, (c) the possible influence of treatment on continued risk behavior, and (d) behavioral research in HIV prevention and care policy areas. Advances in HIV medical care have created important new opportunities for health psychologists to contribute to the well-being of persons with HIV/AIDS.
蛋白酶抑制剂联合疗法可以降低艾滋病毒载量，改善免疫系统功能，并降低艾滋病导致的死亡率。这些医学进展给艾滋病毒/艾滋病的行为研究带来了一系列重要的新问题。本文回顾了艾滋病毒联合治疗方案的进展以及这些方案中涉及的行为因素，并重点关注四个关键的行为研究领域：(a) 开发促进治疗依从性的干预措施；(b) 在针对该疾病的新治疗背景下对艾滋病毒/艾滋病的心理应对；(c) 治疗对持续风险行为的可能影响；以及 (d) 艾滋病毒预防和护理政策领域的行为研究。艾滋病毒医疗护理的进展为健康心理学家为艾滋病毒/艾滋病患者的福祉做出贡献创造了重要的新机会。
